Evoke Pharma INC

Evoke Pharma, Inc. has completed its acquisition by QOL Medical, LLC, becoming a wholly-owned subsidiary and delisting from Nasdaq.

Evoke Pharma announced its acquisition by QOL Medical for $11.00 per share in cash, alongside reporting a 61% year-over-year increase in third-quarter net product sales.

Evoke Pharma has entered into a definitive agreement to be acquired by QOL Medical for $11.00 per share in cash, representing a 139.7% premium.

Evoke Pharma reported a 47% year-over-year increase in GIMOTI net product sales for Q2 2025, reaching $3.8 million, and confirmed its full-year 2025 revenue guidance of $16 million.

Evoke Pharma announced the issuance of a new U.S. patent for its product GIMOTI, extending intellectual property protection until November 2038.

Evoke Pharma, Inc. announced it has received a Notice of Allowance for a U.S. patent application covering GIMOTI, extending its market exclusivity for the gastroparesis treatment until December 2036.

Evoke Pharma reported strong Q3 2025 sales growth for Gimoti and announced a definitive merger agreement to be acquired by QOL Medical for $11.00 per share in cash.

Evoke Pharma reported significant revenue growth for its Gimoti nasal spray in the second quarter of 2025, yet continues to face substantial doubt regarding its ability to continue as a going concern.

Evoke Pharma's Q1 2025 shows a significant increase in net product sales of Gimoti, but the company expresses substantial doubt about its ability to continue as a going concern due to potential termination of the Eversana agreement and the need for additional funding.

Evoke Pharma's Q3 2024 results show a significant increase in net product sales, but the company expresses substantial doubt about its ability to continue as a going concern.

Evoke Pharma saw a significant increase in net product sales and made progress towards Nasdaq listing compliance in the second quarter of 2024, while still facing going concern challenges.

Evoke Pharma's Q1 2024 results show a significant increase in net product sales of Gimoti, but the company still faces substantial doubt about its ability to continue as a going concern.

Evoke Pharma's 10-K filing highlights a significant increase in Gimoti sales, but also acknowledges substantial doubt about the company's ability to continue as a going concern due to recurring losses.

Evoke Pharma has amended its annual report to restate financial statements due to a classification error related to a note payable, also identifying a material weakness in internal controls.

Evoke Pharma's 2023 annual report highlights increased Gimoti sales and ongoing efforts to manage costs and secure future funding.

Nantahala Capital Management, a 10% owner of Evoke Pharma Inc., disposed of all its common stock and warrants following the company's merger with QOL-EOS Merger Sub, Inc.

Evoke Pharma director Greg Pyszczymuka's stock options were canceled and converted to cash following the company's merger with QOL Medical, LLC.

Evoke Pharma director Benjamin C. Smeal cashed out all his stock options following the company's merger with QOL Medical, LLC, effective December 17, 2025.

Evoke Pharma's Chief Medical Officer reported the disposition of common stock and cash-out of stock options following the company's acquisition by QOL Medical.

Evoke Pharma Director Cam L. Garner reports the disposition of common stock and cash conversion of stock options following the company's acquisition by QOL Medical, LLC.

Evoke Pharma Director Malcolm R. Hill reported the sale of common stock and cancellation of stock options following the company's acquisition by QOL Medical, LLC for $11.00 per share.

Evoke Pharma will hold its annual stockholders meeting on May 21, 2025, to vote on director elections, auditor ratification, executive compensation, and the frequency of executive compensation votes.

Evoke Pharma announces its 2025 annual stockholders meeting to be held virtually on May 21, 2025, featuring proposals including director elections, auditor ratification, and executive compensation votes.

Evoke Pharma files an amendment to its annual report to restate financial statements due to a classification error related to a note payable to Eversana, impacting interim periods in 2023.

Evoke Pharma's annual stockholders meeting will take place on May 22, 2024, featuring proposals including director elections, auditor ratification, executive compensation, increasing authorized shares, a potential reverse stock split, and amending the equity incentive plan.

Evoke Pharma's upcoming annual meeting will address critical proposals including director elections, auditor ratification, executive compensation, a potential reverse stock split, and an increase in authorized common stock.

Evoke Pharma is seeking to raise capital through a public offering of common stock units and pre-funded warrant units to fund operations and commercialization activities.

Evoke Pharma is launching an offering of common stock and pre-funded warrant units to raise approximately $6.3 million for working capital and general corporate purposes.

Nantahala Capital Management and its principals have ceased beneficial ownership of Evoke Pharma Inc following its acquisition at $11.00 per share.

Roger M. Klein and the Krieger Charitable Trust acquired a 10.5% stake in Evoke Pharma Inc. following the announcement of a tender offer by QOL Medical, LLC at $11.00 per share.

Nantahala Capital Management and its principals have affirmed their support for Evoke Pharma's acquisition by QOL Medical at $11.00 per share.

Nantahala Capital Management, along with its principals, has initiated discussions with Evoke Pharma, Inc. regarding the appointment of a second board designee, while maintaining a beneficial ownership of 15.99% of the company's common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G indicating their beneficial ownership of Evoke Pharma Inc. common stock has fallen below the 5% threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have reported a 10.5% beneficial ownership stake in Evoke Pharma Inc. common stock.

Laurence W. Lytton has filed an amended Schedule 13G, reporting beneficial ownership of 3.9% of Evoke Pharma Inc's common stock, primarily through warrants, as a passive investor.

Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has filed an amended Schedule 13G disclosing a 9.99% beneficial ownership stake in Evoke Pharma, Inc., comprising common shares and warrants, subject to a beneficial ownership limitation.

Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has filed an amended Schedule 13G disclosing a 9.99% beneficial ownership stake in Evoke Pharma, Inc., primarily held through The Denise and Michael Kellen Foundation.